交易 Axonics, Inc. - AXNX CFD
Market is not available at the moment
Market information is presented
as of 2023-09-21
- 概括
交易条件
| 价差 | - | ||||||||
|
多头隔夜费
Long position overnight fee
前往平台 | -0.026151% | ||||||||
|
空头隔夜费
Short position overnight fee
前往平台 | 0.003929% | ||||||||
| 隔夜费时间 | 21:00 (UTC) | ||||||||
| 最小交易量 | 1 | ||||||||
| 货币 | USD | ||||||||
| 保证金 | 5% | ||||||||
| 上市交易所 | United States of America | ||||||||
| 交易费 | 0% |
*Information provided by Capital.com
Axonics Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Date | 平仓 | Change | Change (%) | 開倉 | High | Low |
|---|
Axonics, Inc. Events
| 时间（协调世界时） (UTC) | 国家 | 事件 |
|---|---|---|
| Monday, October 30, 2023 | ||
| 时间（协调世界时） (UTC) 10:59 | 国家 US
| 事件 Q3 2023 Axonics Inc Earnings Release Q3 2023 Axonics Inc Earnings ReleaseForecast（预报） -上一页 - |
| Wednesday, February 28, 2024 | ||
| 时间（协调世界时） (UTC) 10:59 | 国家 US
| 事件 Q4 2023 Axonics Inc Earnings Release Q4 2023 Axonics Inc Earnings ReleaseForecast（预报） -上一页 - |
- 年度
- 每季度
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| 总收入 | 273.702 | 180.29 | 111.535 | 13.82 | 0.707 |
| 收入 | 273.702 | 180.29 | 111.535 | 13.82 | 0.707 |
| 收入成本，共计 | 76.037 | 64.572 | 44.444 | 6.49 | 0.356 |
| 毛利 | 197.665 | 115.718 | 67.091 | 7.33 | 0.351 |
| 总营业费用 | 338.648 | 252.098 | 165.295 | 94.419 | 32.844 |
| 销售/一般/行政费用，总计 | 196.257 | 138.574 | 91.681 | 67.748 | 13.086 |
| 研究与开发 | 34.41 | 37.297 | 29.17 | 20.181 | 19.402 |
| 营业收入 | -64.946 | -71.808 | -53.76 | -80.599 | -32.137 |
| 利息收入（费用），非经营净值 | 2.699 | -7.386 | 0.761 | 2.974 | 0.698 |
| Gain (Loss) on Sale of Assets | -0.069 | -0.091 | -0.041 | 0 | |
| 其他，净值 | -1.874 | -2.309 | -1.043 | ||
| 税前净收入 | -62.316 | -79.285 | -54.914 | -79.934 | -32.482 |
| 税后净收入 | -59.698 | -80.067 | -54.915 | -79.935 | -32.483 |
| 未计算非常项目前的净收益 | -59.698 | -80.067 | -54.915 | -79.935 | -32.483 |
| 净收入 | -59.698 | -80.067 | -54.915 | -79.935 | -32.483 |
| 普通股股东可获收益 (不含非经常性项目) | -59.698 | -80.067 | -54.915 | -79.935 | -32.483 |
| 普通股股东可获收益 (含非經常性項目) | -59.698 | -80.067 | -54.915 | -79.935 | -32.483 |
| 摊薄净收入 | -59.698 | -80.067 | -54.915 | -79.935 | -32.483 |
| 摊薄后加权平均股 | 46.6845 | 43.0723 | 36.9813 | 28.5673 | 27.8069 |
| 扣除特别项目的每股摊薄盈利 | -1.27875 | -1.8589 | -1.48494 | -2.79813 | -1.16816 |
| Dividends per Share - Common Stock Primary Issue | |||||
| 每股正常摊薄盈利 | -0.96367 | -1.79091 | -1.48422 | -2.79813 | -1.16816 |
| Depreciation / Amortization | 9.383 | 7.241 | |||
| 异常费用（收入） | 22.561 | 4.414 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| 总收入 | 92.894 | 70.65 | 85.918 | 70.384 | 68.98 |
| 收入 | 92.894 | 70.65 | 85.918 | 70.384 | 68.98 |
| 收入成本，共计 | 22.704 | 18.15 | 22.951 | 19.124 | 18.784 |
| 毛利 | 70.19 | 52.5 | 62.967 | 51.26 | 50.196 |
| 总营业费用 | 104.964 | 85.016 | 89.527 | 86.759 | 90.409 |
| 销售/一般/行政费用，总计 | 54.983 | 54.822 | 54.088 | 49.14 | 49.953 |
| 研究与开发 | 8.949 | 8.056 | 8.103 | 7.936 | 7.135 |
| Depreciation / Amortization | 2.279 | 2.222 | 2.271 | 2.317 | 2.332 |
| 异常费用（收入） | 16.049 | 1.766 | 2.114 | 8.242 | 12.205 |
| 营业收入 | -12.07 | -14.366 | -3.609 | -16.375 | -21.429 |
| 利息收入（费用），非经营净值 | 4.424 | 4.311 | 3.82 | -0.397 | -0.479 |
| 税前净收入 | -7.646 | -10.055 | 0.143 | -16.772 | -21.908 |
| 税后净收入 | -7.342 | -9.248 | 0.665 | -16.252 | -21.443 |
| 未计算非常项目前的净收益 | -7.342 | -9.248 | 0.665 | -16.252 | -21.443 |
| 净收入 | -7.342 | -9.248 | 0.665 | -16.252 | -21.443 |
| 普通股股东可获收益 (不含非经常性项目) | -7.342 | -9.248 | 0.665 | -16.252 | -21.443 |
| 普通股股东可获收益 (含非經常性項目) | -7.342 | -9.248 | 0.665 | -16.252 | -21.443 |
| 摊薄净收入 | -7.342 | -9.248 | 0.665 | -16.252 | -21.443 |
| 摊薄后加权平均股 | 49.0884 | 48.5791 | 48.1823 | 47.2082 | 45.311 |
| 扣除特别项目的每股摊薄盈利 | -0.14957 | -0.19037 | 0.0138 | -0.34426 | -0.47324 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| 每股正常摊薄盈利 | 0.17308 | -0.16674 | 0.04325 | -0.23078 | -0.29816 |
| Gain (Loss) on Sale of Assets | -0.069 | ||||
| 其他，净值 | 0.001 |
- 年度
- 每季度
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| 流动资产总额 | 465.075 | 321.317 | 327.946 | 211.68 | 165.34 |
| 现金和短期投资 | 357.211 | 220.878 | 241.181 | 183.674 | 157.524 |
| 现金等价物 | 238.846 | 220.878 | 241.181 | 171.082 | 98.306 |
| 短期投资 | 118.365 | 0 | 12.592 | 59.218 | |
| 应收账款总额，净额 | 44.817 | 29.044 | 18.27 | 7.879 | 0.427 |
| 應收賬款 - 貿易，淨額 | 44.817 | 29.044 | 18.27 | 7.879 | 0.427 |
| 總庫存 | 55.765 | 64.946 | 63.06 | 15.659 | 3.673 |
| 預付的費用 | 7.282 | 6.449 | 5.435 | 4.468 | 3.716 |
| 總資産 | 659.353 | 547.945 | 342.206 | 219.822 | 171.906 |
| 物業/廠房/設備，總計 - 淨額 | 12.998 | 14.015 | 13.428 | 7.247 | 2.784 |
| 物業/廠房/設備，總計 - 總額 | 20.534 | 19.559 | 17.243 | 10.307 | 4.768 |
| 累計折舊，總計 | -7.536 | -5.544 | -3.815 | -3.06 | -1.984 |
| 無形資産，淨額 | 86.253 | 106.469 | 0.196 | 0.311 | 0.426 |
| 其他長期資産，總計 | 0.613 | 0.634 | 0.636 | 0.584 | 3.356 |
| 流動負債總額 | 65.247 | 26.868 | 45.682 | 12.033 | 5.887 |
| 應付賬款 | 9.07 | 7.654 | 10.66 | 5.882 | 3.436 |
| 預提費用 | 23.577 | 19.214 | 13.912 | 6.151 | 1.683 |
| 應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
| 負債總額 | 89.214 | 65.507 | 54.836 | 36.819 | 28.631 |
| 長期債務總額 | 0 | 0 | 0 | 20.336 | 22.744 |
| 長期債務 | 0 | 20.336 | 19.463 | ||
| 資本租賃義務 | 3.281 | ||||
| 少數股權 | |||||
| 總權益 | 570.139 | 482.438 | 287.37 | 183.003 | 143.275 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| 普通股 | 0.005 | 0.005 | 0.004 | 0.003 | 0.003 |
| 額外實收資本 | 969.545 | 803.559 | 522.296 | 363.012 | 243.337 |
| 留存收益（累計赤字） | -374.264 | -314.566 | -234.499 | -179.584 | -99.649 |
| 其他權益，總計 | -25.147 | -6.56 | -0.431 | -0.428 | -0.416 |
| 總負債和股東權益 | 659.353 | 547.945 | 342.206 | 219.822 | 171.906 |
| 已發行普通股總數 | 49.5467 | 46.3302 | 39.931 | 34.111 | 27.8069 |
| 長期債務的當前部分/資本租賃 | 0 | 21.11 | 0.768 | ||
| 其他負債，總計 | 7.555 | 19.422 | 9.154 | 4.45 | |
| 商譽，淨額 | 94.414 | 105.51 | |||
| 遞延所得稅 | 16.412 | 19.217 | |||
| 其他流動負債，總計 | 32.6 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| 流动资产总额 | 469.671 | 465.075 | 449.361 | 313.127 | 307.433 |
| 现金和短期投资 | 357.062 | 357.211 | 350.013 | 213.234 | 213.18 |
| 现金等价物 | 240.105 | 238.846 | 241.331 | 203.236 | 213.18 |
| 应收账款总额，净额 | 40.2 | 44.817 | 36.96 | 36.115 | 27.425 |
| 應收賬款 - 貿易，淨額 | 40.2 | 44.817 | 36.96 | 36.115 | 27.425 |
| 總庫存 | 66.067 | 55.765 | 57.827 | 58.412 | 61.876 |
| 預付的費用 | 6.342 | 7.282 | 4.561 | 5.366 | 4.952 |
| 總資産 | 665.691 | 659.353 | 632.278 | 514.088 | 525.571 |
| 物業/廠房/設備，總計 - 淨額 | 12.917 | 12.998 | 13.503 | 13.828 | 13.707 |
| 物業/廠房/設備，總計 - 總額 | 21.038 | 20.534 | 20.705 | 20.497 | 19.794 |
| 累計折舊，總計 | -8.121 | -7.536 | -7.202 | -6.669 | -6.087 |
| 商譽，淨額 | 96.581 | 94.414 | 86.942 | 94.852 | 102.558 |
| 無形資産，淨額 | 85.888 | 86.253 | 81.787 | 91.627 | 101.179 |
| 其他長期資産，總計 | 0.634 | 0.613 | 0.685 | 0.654 | 0.694 |
| 流動負債總額 | 66.17 | 65.247 | 60.843 | 29.859 | 25.519 |
| 應付賬款 | 14.737 | 9.07 | 9.972 | 10.207 | 10.39 |
| 預提費用 | 17.033 | 23.577 | 20.371 | 19.652 | 15.129 |
| 應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
| 長期債務的當前部分/資本租賃 | |||||
| 負債總額 | 89.085 | 89.214 | 82.76 | 76.362 | 62.139 |
| 長期債務總額 | 0 | 0 | 0 | 0 | 0 |
| 長期債務 | |||||
| 其他負債，總計 | 7.178 | 7.555 | 7.96 | 30.721 | 19.056 |
| 總權益 | 576.606 | 570.139 | 549.518 | 437.726 | 463.432 |
| 普通股 | 0.005 | 0.005 | 0.005 | 0.005 | 0.005 |
| 額外實收資本 | 982.189 | 969.545 | 960.627 | 820.526 | 812.141 |
| 留存收益（累計赤字） | -383.512 | -374.264 | -374.929 | -358.677 | -337.234 |
| 其他權益，總計 | -22.076 | -25.147 | -36.185 | -24.128 | -11.48 |
| 總負債和股東權益 | 665.691 | 659.353 | 632.278 | 514.088 | 525.571 |
| 已發行普通股總數 | 50.1107 | 49.5467 | 49.4796 | 47.1177 | 47.0029 |
| 遞延所得稅 | 15.737 | 16.412 | 13.957 | 15.782 | 17.564 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| 短期投资 | 116.957 | 118.365 | 108.682 | 9.998 | |
| 其他流動負債，總計 | 34.4 | 32.6 | 30.5 |
- 年度
- 每季度
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| 净收入/起跑线 | -59.698 | -80.067 | -54.915 | -79.935 | -32.483 |
| 经营活动产生的现金 | 3.191 | -47.306 | -83.742 | -83.454 | -31.37 |
| 经营活动产生的现金 | 11.721 | 9.126 | 1.741 | 1.191 | 0.946 |
| 非现金物品 | 54.099 | 33.446 | 16.465 | 9.668 | 3.022 |
| Cash Taxes Paid | 0.667 | 0.001 | 0.001 | 0.001 | 0.001 |
| 已付现金利息 | 0.001 | 2.178 | 1.102 | 1.436 | 0.751 |
| 营运资金的变化 | -2.931 | -9.811 | -47.033 | -14.378 | -2.855 |
| 投资活动产生的现金 | -120.354 | -143.002 | 9.654 | 45.287 | -60.05 |
| 资本支出 | -2.223 | -2.261 | -2.938 | -1.339 | -1.228 |
| 其他投资现金流量项目，总计 | -118.131 | -140.741 | 12.592 | 46.626 | -58.822 |
| 融资活动产生的现金 | 133.968 | 170.513 | 144.19 | 110.955 | 165.342 |
| 融资现金流项目 | -0.192 | -11.378 | -9.013 | -7.141 | -12.292 |
| 股票的发行（报废），净额 | 134.16 | 208.007 | 153.203 | 118.096 | 157.634 |
| 债务的发行（退还），净额 | 0 | -26.116 | 0 | 0 | 20 |
| 外汇效应 | 1.163 | -0.508 | -0.003 | -0.012 | -0.014 |
| 现金净变化 | 17.968 | -20.303 | 70.099 | 72.776 | 73.908 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -9.248 | -59.698 | -60.363 | -44.111 | -22.668 |
| Cash From Operating Activities | -0.781 | 3.191 | -6.162 | -10.009 | -9.167 |
| Cash From Operating Activities | 2.813 | 11.721 | 8.841 | 5.92 | 3.029 |
| Non-Cash Items | 11.331 | 54.099 | 41.704 | 25.385 | 5.889 |
| Cash Taxes Paid | 0 | 0.667 | 0.644 | 0.639 | 0 |
| Cash Interest Paid | 0 | 0.001 | 0.001 | 0.001 | 0.001 |
| Changes in Working Capital | -5.677 | -2.931 | 3.656 | 2.797 | 4.583 |
| Cash From Investing Activities | 0.694 | -120.354 | -110.324 | -10.923 | -0.291 |
| Capital Expenditures | -0.794 | -2.223 | -1.888 | -0.925 | -0.291 |
| Other Investing Cash Flow Items, Total | 1.488 | -118.131 | -108.436 | -9.998 | 0 |
| Cash From Financing Activities | 1.93 | 133.968 | 133.807 | 1.924 | 1.444 |
| Financing Cash Flow Items | -0.192 | -0.192 | 0 | 0 | |
| Issuance (Retirement) of Stock, Net | 1.93 | 134.16 | 133.999 | 1.924 | 1.444 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | 0 | |
| Foreign Exchange Effects | -0.584 | 1.163 | 3.132 | 1.366 | 0.316 |
| Net Change in Cash | 1.259 | 17.968 | 20.453 | -17.642 | -7.698 |
| Deferred Taxes |
Axonics, Inc. Company profile
关于 Axonics Inc.
Axonics, Inc.是一家医疗技术公司。 它从事为膀胱和肠道功能障碍患者开发和商业化的产品。 膀胱和肠道功能障碍包括植入式骶骨神经调节（SNM）系统，用于治疗尿急失禁（UUI）和尿频（UUF），合称膀胱过度活动症（OAB），以及大便失禁（FI）和非梗阻性尿潴留（UR），还有一种尿道膨胀剂，用于治疗女性压力性尿失禁（SUI）。 该公司设计并开发了可充电的骶神经调节（SNM）系统（r-SNM系统），该系统向目标骶神经提供温和的电脉冲，以恢复与大脑的正常交流，从而减轻OAB、UR和FI的症状。 该公司有两项与r-SNM系统有关的研究，一项是欧洲研究RELAX-OAB，另一项是美国的关键研究ARTISAN-SNM。 该公司提供尿道膨胀剂Bulkamid，用于治疗压力性尿失禁。
| Industry: | Medical Devices & Implants |
26 Technology Dr
IRVINE
CALIFORNIA 92618
US
人们也观看
还在找一位您可以信任的经纪商吗？
加入成为全球555,000万多名交易者的一份子，选择利用Capital.com进行交易吧。